C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H1 2019

Global Markets Direct’s, ‘C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2019’, provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders and Respiratory under development targeting C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AFFiRiS AG

ChemoCentryx Inc

Dompe Farmaceutici SpA

Innate Pharma SA

Integral Molecular Inc

MorphoSys AG

Prommune Inc

Teva Pharmaceutical Industries Ltd

AFFiRiS AG

ChemoCentryx Inc

Dompe Farmaceutici SpA

Innate Pharma SA

Integral Molecular Inc

MorphoSys AG

Prommune Inc

Teva Pharmaceutical Industries Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Overview ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Overview

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Companies Involved in Therapeutics Development

AFFiRiS AG

ChemoCentryx Inc

Dompe Farmaceutici SpA

Innate Pharma SA

Integral Molecular Inc

MorphoSys AG

Prommune Inc

Teva Pharmaceutical Industries Ltd

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Drug Profiles

ALS-205 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DF-2593A – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize C5aR for Periodontitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-67 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPH-5401 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize C5AR1 for Immunological Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-210 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMX-205 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target C5a for Alzheimer's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Dormant Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Discontinued Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Product Development Milestones

Featured News & Press Releases

Jan 24, 2019: ChemoCentryx announces withdrawal of phase II-based conditional marketing authorisation (CMA) application for ANCA-associated vasculitis in Europe, phase III advocate trial data release planned for Q4 2019

Oct 25, 2018: ChemoCentryx announces presentation of data on Avacopan, a complement 5a receptor inhibitor, at ASN Kidney Week 2018

Sep 12, 2018: Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi) in solid tumors

May 23, 2018: ChemoCentryx Announces Presentation On Avacopan at the 55th ERA-EDTA Congress

Apr 11, 2018: ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting

Jan 04, 2018: Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency

Nov 03, 2017: ChemoCentryx Presents Data On Avacopan at ASN Kidney Week 2017

Sep 11, 2017: Innate Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference

Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan

May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy

Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy

Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan

Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)

Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy

Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by AFFiRiS AG, H1 2019

Pipeline by ChemoCentryx Inc, H1 2019

Pipeline by Dompe Farmaceutici SpA, H1 2019

Pipeline by Innate Pharma SA, H1 2019

Pipeline by Integral Molecular Inc, H1 2019

Pipeline by MorphoSys AG, H1 2019

Pipeline by Prommune Inc, H1 2019

Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports